Company Overview

Evaxion A/S is a clinical-stage biotechnology company focused on the development of AI-powered immunotherapies. The company operates primarily within the biotechnology and pharmaceutical research industries, specializing in precision vaccines and immuno-oncology. Its core strategy is to leverage proprietary artificial intelligence platforms to design novel therapies that activate the human immune system against cancer and infectious diseases.

Founded in 2008 in Denmark, Evaxion evolved from academic research into a publicly listed company on Nasdaq, trading under the ticker EVAX. The company’s differentiation lies in its integrated AI platforms that identify disease-specific antigens and optimize immune responses, positioning Evaxion within the emerging field of computational immunology. Its programs primarily target high-unmet-need oncology indications and selected infectious diseases, with activities focused on early- and mid-stage clinical development.

Business Operations

Evaxion’s operations are organized around multiple technology-driven platforms and development programs rather than commercialized products, as the company does not currently generate product revenue. Its core business segments include AI-Immunology™ platforms, notably PIONEER™, EDEN™, and RAVEN™, which are designed to identify cancer neoantigens, bacterial antigens, and viral targets, respectively. These platforms support Evaxion’s internal pipeline of therapeutic cancer vaccines and infectious disease vaccines.

The company conducts research and development primarily in-house and through collaborations with academic institutions and biotechnology partners. Operations are concentrated in Denmark, with clinical trials conducted internationally through contract research organizations. Evaxion does not currently report significant revenue from commercial sales, with funding historically derived from equity offerings, partnerships, and grants.

Strategic Position & Investments

Evaxion’s strategic direction centers on advancing its lead oncology and infectious disease vaccine candidates through clinical development while validating its AI platforms through partnerships. Key growth initiatives include progressing personalized and off-the-shelf cancer vaccine programs and expanding applications of its AI technology across multiple disease areas. The company has entered into strategic collaborations with pharmaceutical and biotechnology partners to co-develop vaccine candidates and leverage external development capabilities.

The company has made targeted investments in platform development rather than large-scale acquisitions. Its portfolio includes wholly owned development programs rather than diversified equity investments. Evaxion’s focus on AI-driven antigen discovery places it at the intersection of biotechnology and machine learning, an area of increasing strategic importance within drug development.

Geographic Footprint

Evaxion is headquartered in Hørsholm, Denmark, which serves as its primary research and administrative hub. The company’s operational footprint is primarily European, with Denmark as the center of laboratory and corporate functions. Clinical development activities extend to North America and other parts of Europe, reflecting the global nature of its clinical trials.

While Evaxion does not maintain extensive physical infrastructure outside Denmark, it has an international presence through collaborations, clinical trial sites, and engagement with global regulatory authorities. Its public listing in the United States provides access to international capital markets and a broader investor base.

Leadership & Governance

Evaxion is led by an executive team with experience in biotechnology, pharmaceuticals, and immunology, emphasizing scientific rigor and data-driven decision-making. The leadership philosophy centers on leveraging advanced computational tools to accelerate drug discovery while maintaining disciplined clinical development and governance standards consistent with public company requirements.

Key executives include:

• Per Norlén – Chief Executive Officer
• Thomas Høegh – Chief Financial Officer
• Søren Bregenholt – Chief Scientific Officer
• Birgitte Volck – Chair of the Board of Directors

The company is governed by a board with experience across life sciences, public markets, and strategic leadership, supporting oversight of long-term strategy, risk management, and shareholder interests.